{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for vitamin root_relationships_comments in Relationship Comments (approximate match)
Status:
Investigational
Source:
NCT02181491: Not Applicable Interventional Completed Cocaine Dependence
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02003092: Phase 1/Phase 2 Interventional Terminated Solid Tumor
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03110549: Phase 1 Interventional Terminated Human Immunodeficiency Virus
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MX-100 (also known as PL-100) is a benzenesulfonamide derivative patented by Pharmacor Inc as HIV aspartyl protease inhibitor. MX-100 retained excellent antiviral activity against almost all of these protease inhibitor-resistant viruses and that its performance in this regard was superior to those of atazanavir, amprenavir, indinavir, lopinavir, nelfinavir, and saquinavir. In almost every case, the increase in the EC50 for MX-100 observed with viruses containing multiple mutations in protease was far less than that obtained with the other drugs. Preclinical studies showed that MX-100 possessed suboptimal solubility and pharmacokinetic, (PK) properties, possibly hindering further development. MX-100 successfully completed preclinical and clinical development (phase I in healthy volunteers) and have been licensed to Merck in 2006
Status:
Investigational
Source:
NCT03886662: Phase 1/Phase 2 Interventional Recruiting Myelodysplastic Syndromes
(2019)
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Investigational
Source:
NCT03539575: Not Applicable Interventional Active, not recruiting Drug Dependence
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
11C-JHU75528 (also known as 11C-OMAR) is a radiotracer with suitable imaging properties for quantification of cannabinoid receptor, CB1R in the human brain. 11C-JHU75528 is participating in an ongoing phase I clinical trial to examine whether the use of cannabis alters CB1R availability in females and if the severity of cannabis withdrawal is correlated with CB1 receptor availability.
Status:
Investigational
Source:
NCT02204579: Phase 2 Interventional Completed Autosomal Dominant Hypocalcemia (ADH)
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01374321: Phase 2 Interventional Completed Acute Myocardial Infarctus
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03472326: Phase 2 Interventional Terminated HIV-1-infection
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01279590: Phase 2 Interventional Completed Myalgia
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00676299: Phase 1 Interventional Completed Protein Kinase Inhibitors
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
